Plus Therapeutics subsidiary CNSide Diagnostics enrolls in Medicare
Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, has successfully enrolled in the Medicare program and received a Provider Transaction Access Number (PTAN) from CMS. This critical milestone establishes CNSide Diagnostics as a Medicare-enrolled clinical laboratory, enabling the submission of claims for its CNSide® Cerebrospinal Fluid (CSF) Assay Platform, including the tumor cell enumeration (TCE) test. The enrollment expands patient access to approximately half of the U.S. Medicare population, building on the existing 81 million commercial covered lives, with a goal of achieving over 150 million covered lives by 2026. This move is a key step in the commercialization strategy, facilitating billing for Traditional Medicare and paving the way for expansion into Medicare Advantage and Medicaid populations.
Key Highlights
- CNSide Diagnostics, a Plus Therapeutics subsidiary, enrolled in the Medicare program.
- Received a Provider Transaction Access Number (PTAN) from CMS.
- Enables billing for CNSide® CSF Assay Platform, including the TCE test.
- Expands access to approximately half of the U.S. Medicare population.
- Adds to existing ~81 million commercial covered lives.
- Targets 150 million+ covered lives by 2026.
- CPT code 0640U for CNSide CSF TCE Test effective for billing July 1, 2026.